Oct 2026· Radiographics· Vol 46, pp. e250146 - e250146· 3 citations· 61 references
Medicine
TL;DR
The authors aim to critically appraise current screening strategies, highlight emerging technologies in imaging and biomarkers, and discuss their potential to transform early detection and improve clinical outcomes in high-risk populations.
Abstract
Pancreatic cancer remains one of the most lethal malignancies, with an overall 5-year survival rate of approximately 13%. The poor prognosis is primarily due to late-stage diagnosis, as early-stage disease is often asymptomatic. Screening for pancreatic cancer in high-risk individuals offers the potential for early detection, timely intervention, and improved survival outcomes. Individuals at elevated risk for pancreatic cancer, i.e., family history and/ or predisposing genes for pancreatic cancer, or certain inherited syndromes, and patients with precursor lesions and precancerous lesions, are considered suitable candidates for screening. Imaging is recognized as an important tool for diagnosis and staging of pancreatic cancer. Evidence supports the use of endoscopic ultrasound (EUS), magnetic resonance imaging (MRI), and computed tomography (CT) as primary imaging modalities to facilitate early detection. Screening intervals and imaging strategies vary in high-risk individuals and those with precursor or precancerous lesions. While conventional imaging plays a key role in diagnosis and staging, it often fails to detect visually occult disease, an area where artificial intelligence-enhanced imaging offers potential. These advancements have the potential to improve detection of early pancreatic cancer in prediagnostic CT and MRI. In parallel, the development of novel serum biomarkers with greater sensitivity and specificity provides promising avenues for non-invasive screening. Despite these advances, there remains a critical unmet need for validated, cost-effective, and scalable tools. This review aims to critically appraise current screening strategies, highlight emerging technologies in imaging and biomarkers, and discuss their potential to transform early detection and improve clinical outcomes in high-risk populations.
A multimodal approach combining imaging, biomarkers, and emerging technologies is needed to improve outcomes, and greater awareness among primary care physicians and continued development of liquid biopsy and AI tools may improve outcomes.
Maria Sicińska, Małgorzata Katra, Mikołaj Szczęsny et al.· Journal of Education, Health...· 0 citations
It is emphasized that the future effectiveness of PDAC prevention lies in refined risk stratification through universal germline testing, the integration of polygenic and environmental data, and the provision of comprehensive psychosocial support to manage the emotional impact of surveillance.
D. Campa, C. Rizzato, A. Kataki et al.· Revista Espanola de Enfermed...· 0 citations
Exocrine pancreatic cancer, particularly Pancreatic Ductal Adenocarcinoma, is regarded as one of the most aggressive cancers with a poor prognosis. Its bleak outlook mainly results from its silent progression, late diagnosis, and unreliable early detection methods. Globally, PC ranks among the leading causes of cancer-...
R. K. Sharma, Alpa Singh, Gaurav Sharma et al.· Frontiers in Gastroenterolog...· 0 citations
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and most often arises in patients with chronic liver disease and cirrhosis. Since curative treatment options are largely limited to early-stage disease, effective surveillance strategies are essential to improve outcomes. Cu...
Kathryn J. Fowler, A. Kamaya, S. Rodgers et al.· Radiographics· 0 citations
Evidence shows that EOCRC is disproportionately distal or rectal and is often diagnosed at stage III or IV, and earlier symptom recognition, risk-based assessment, germline testing, and timely colonoscopy are therefore central to reducing preventable late diagnoses.
Eduarda de Oliveira Mainardi, Fabrício da Cunha Moraes, Manuella Hassan Salman· International Health Science...· 0 citations
Head and neck cancers (HNCs) represent one of the most prevalent and lethal types of cancer, accounting for 4.7% of annual cancer new cases and 4.9% of cancer-related mortalities. These high prevalence and mortality rates have positioned HNCs as a global health issue. Despite advances in disease treatment methods, the...
A. Yumashev, S. Amonov, Aisher Soliyev et al.· Clinica chimica acta; intern...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.